Study of zanubrutinib and tislelizumab for lymphoma after CAR-T
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have large B-cell lymphoma that came back or didn't get better after CAR-T cell therapy (within 6 weeks of that treatment).
- You have at least one tumor that can be seen on a scan and is at least 2 cm (about the size of a grape) in a lymph node, or 1 cm elsewhere.
- Your blood counts (hemoglobin, platelets, and neutrophils) must be above certain levels, though they can be supported with transfusions or growth factors.
- You cannot have taken a BTK inhibitor (like ibrutinib) or a PD-1 inhibitor (like pembrolizumab) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
This study tests whether taking a daily pill called zanubrutinib after CAR-T cell therapy can help keep your lymphoma from coming back. If you have non-Hodgkin B-cell lymphoma and you are about to start or are already taking zanubrutinib after CAR-T treatment, you may be eligible.
This study tests whether adding a type of maintenance therapy after CAR-T cell treatment helps people with low-risk B-cell lymphoma that has returned or not responded to standard treatments. It compares the standard CAR-T approach to one with extra immune-supporting treatment.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.